Sequence Variants of Peroxisome Proliferator-Activated Receptor-Gamma Gene and the Clinical Courses of Patients with End-Stage Renal Disease

Abstract EN

Background.

PPAR-γ single nucleotide polymorphisms (SNPs) reportedly play an important role in determining metabolic risk among diverse population.

Whether PPAR-γ SNPs affect the clinical courses in ESRD patients is unknown.

Methods.

From a multicenter cohort, we identified 698 patients with prevalent ESRD between 2002 and 2003, and other 782 healthy subjects as control.

Two PPAR-γ SNPs, Pro12Ala (rs1801282) and C161T (rs3856806), were genotyped and their association with ESRD was examined.

Both groups were prospectively followed until 2007, and the predictability of genotypes for the long-term survival of ESRD patients was analyzed.

Results.

After multivariable-adjusted regression, GG genotype of Pro12Ala was significantly more likely to associate with ESRD ( P < 0.001 ) among patients with non-diabetes-related ESRD.

Cox’s proportional hazard regression showed that both Pro12Ala and C161T polymorphisms were significant predictors of mortality in ESRD patients with DM (Pro12Ala: GG versus other genotypes, hazard ratio [HR] <0.01; P < 0.001 ; for C161T, CC versus TT genotypes, HR 2.86; P < 0.001 ; CT versus TT genotypes, HR 1.93; P < 0.001 ).

Conclusion.

This is the first and largest study to evaluate PPAR-γ SNPs in ESRD patients.

Further mechanistic study is needed to elucidate the role of PPAR-γ among ESRD patients.